A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Inclusion Criteria:

• Participant must be aged greater than or equal (≥)18 years at the time of signingthe informed consent

• Participant has chronic atopic dermatitis (AtD) (according to American Academy ofDermatology Consensus Criteria) that has been present for at least ≥1 year prior toinitiating the study (ie, signing of the informed consent form [ICF]) and with:

1. validated Investigator Global Assessment (vIGA) score ≥3 at Screening andBaseline

2. Eczema Area and Severity Index (EASI) score ≥16 at both Screening and Baseline

3. Peak Pruritus Numerical Rating Scale (PP-NRS) score of ≥4 at both Screening andBaseline

4. ≥10% body surface area (BSA) of AtD involvement at both Screening and Baseline

5. Documented recent history (within 6 months prior to Screening) of inadequateresponse to treatment with topical medications, or study participants for whomtopical treatments are otherwise medically inadvisable (eg, due to importantside effects or safety risks) and who are candidates for systemic therapy

Exclusion Criteria:

• Participant has any history or presence of any medical or psychiatric condition,physical examination finding, laboratory test result, or electrocardiogram (ECG)signal that, in the opinion of the investigator, could constitute a risk when takingthe study intervention; or interfere with the interpretation of data and couldjeopardize or would compromise the study participant's ability to participate inthis study

• Active dermatologic conditions that may confound the diagnosis of AtD or wouldinterfere with assessment of treatment, such as but not limited to scabies,seborrheic dermatitis, cutaneous lymphoma, ichthyosis, psoriasis, active allergic orirritant contact dermatitis

• Presence or family history (first degree) of inflammatory bowel disease (includesCrohn's disease and ulcerative colitis)

• History of chronic or recurrent infections, or a serious or life-threateninginfection within the 6 months prior to the Baseline (including herpes zoster) asjudged by the investigator

• Participants are not permitted to enroll into the study if they meet tuberculosis (TB) exclusion criteria

• Previous treatment with galvokimig

• Participant has relevant safety events to one or more interleukin (IL)-13 biologicresponse modifiers (ie, dupilumab, tralokinumab and lebrikizumab) that resulted indiscontinuation and change of treatment

• All systemic therapies (other than biologics), topical therapies and othertreatments for AtD must be discontinued at least 4 weeks prior to Baseline

• Treatment with biologic agents must discontinued at least 3 months prior to baseline